We Are One Seven LLC bought a new position in Catalent Inc (NYSE:CTLT) during the third quarter, according to its most recent filing with the SEC. The firm bought 7,545 shares of the company’s stock, valued at approximately $343,000.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new position in Catalent during the 2nd quarter valued at $145,000. Moneta Group Investment Advisors LLC lifted its stake in Catalent by 105.0% during the 2nd quarter. Moneta Group Investment Advisors LLC now owns 3,515 shares of the company’s stock valued at $147,000 after acquiring an additional 1,800 shares in the last quarter. Point72 Asia Hong Kong Ltd lifted its stake in Catalent by 35,700.0% during the 1st quarter. Point72 Asia Hong Kong Ltd now owns 3,938 shares of the company’s stock valued at $162,000 after acquiring an additional 3,927 shares in the last quarter. Hartford Investment Management Co. bought a new position in Catalent during the 2nd quarter valued at $220,000. Finally, Rehmann Capital Advisory Group lifted its stake in Catalent by 1,895.9% during the 2nd quarter. Rehmann Capital Advisory Group now owns 5,309 shares of the company’s stock valued at $222,000 after acquiring an additional 5,043 shares in the last quarter. Institutional investors own 91.76% of the company’s stock.
In other news, insider John R. Chiminski sold 130,545 shares of the firm’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $45.32, for a total transaction of $5,916,299.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Donald E. Morel, Jr. bought 10,000 shares of the firm’s stock in a transaction dated Thursday, September 13th. The shares were acquired at an average cost of $43.00 per share, with a total value of $430,000.00. The disclosure for this purchase can be found here. Company insiders own 1.40% of the company’s stock.
Several brokerages have weighed in on CTLT. Zacks Investment Research upgraded Catalent from a “sell” rating to a “hold” rating in a research note on Monday, October 1st. UBS Group began coverage on Catalent in a research note on Tuesday. They set a “neutral” rating and a $48.00 price objective on the stock. JPMorgan Chase & Co. raised their price objective on Catalent from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Wednesday, August 29th. Finally, ValuEngine upgraded Catalent from a “hold” rating to a “buy” rating in a research note on Tuesday, June 26th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Catalent has an average rating of “Buy” and an average target price of $49.33.
Shares of Catalent stock opened at $41.47 on Friday. Catalent Inc has a 1 year low of $36.73 and a 1 year high of $47.87. The firm has a market cap of $6.61 billion, a PE ratio of 26.23, a price-to-earnings-growth ratio of 2.71 and a beta of 1.40. The company has a quick ratio of 1.79, a current ratio of 2.15 and a debt-to-equity ratio of 2.44.
Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, August 28th. The company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.06. Catalent had a return on equity of 20.42% and a net margin of 3.39%. The firm had revenue of $685.30 million during the quarter, compared to analyst estimates of $690.69 million. During the same period last year, the firm posted $0.65 EPS. The business’s revenue was up 11.1% compared to the same quarter last year. Equities analysts expect that Catalent Inc will post 1.72 earnings per share for the current fiscal year.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Further Reading: Outstanding Shares, Buying and Selling Stocks
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.